Stedman Clinical Trials

Recent papers from Stedman Clinical Trials

1. Durability of the benefit of vagus nerve stimulation in markedly treatment-resistant major depression: a RECOVER trial reportThe International Journal of Neuropsychopharmacology · 2025
2. Clinical outcomes of youth at familial risk for bipolar disorder: A 2-year longitudinal, observational studyJournal of Affective Disorders · 2025
3. Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension studyJournal of the European Academy of Dermatology and Venereology · 2025
4. Vagus nerve stimulation in treatment-resistant depression: A one-year, randomized, sham-controlled trialBrain stimulation · 2024
5. Clinical characteristics and treatment exposure of patients with marked treatment-resistant unipolar major depressive disorder: A RECOVER trial reportBrain stimulation · 2024
6. Phase 2b randomized trial of OX40 inhibitor telazorlimab for moderate-to-severe atopic dermatitisJournal of Allergy and Clinical Immunology Global · 2023
7. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B studyJournal of the European Academy of Dermatology and Venereology · 2021
8. A Double‐Blind, Placebo‐Controlled Study With Quetiapine as Adjunct Therapy With Lithium or Divalproex in Bipolar I Patients With Coexisting Alcohol DependenceAlcoholism Clinical and Experimental Research · 2010
9. Beneficial effects of docosahexaenoic acid on cognition in age‐related cognitive declineAlzheimer s & Dementia · 2010
10. P2‐377: A phase 2, double‐blind, placebo‐controlled study to evaluate the safety, tolerability, and effect on cognitive function of AL‐108 after 12 weeks of intranasal administration in subjects with mild cognitive impairmentAlzheimer s & Dementia · 2008